←
ASTRO19,579 posts
ASTRO avatar✓

ASTRO ✓

@ASTRO_org

ASTRO is the American Society for Radiation Oncology. Targeting Cancer Care. Patient education info at rtanswers.org #radonc #medphys #radbio #DEIinRO

◷ Joined April 2009▧ 9,139 Photos and videos
ASTRO avatar
ASTRO@ASTRO_org·15h

Register FREE for ASTRO's next session of Functional Radiation Medicine Grand Rounds: "Radiation Management and Dose Reduction for Nononcologic Conditions" Friday, Dec. 11 | 12:00 p.m. ET David Roberge, MD, Steve Braunstein, MD, PhD, and Philip Wong, MD, MSc will discuss how radiation biology informs dose selection and share practical considerations for treatment planning LDRT. Register now: bit.ly/4zOpc19

Post attachment
ASTRO avatar
ASTRO@ASTRO_org·18h

In honor of International Day of Medical Physics, RO-ILS released a new 🌟 Great Catch highlighting a medical physicist who identified an upstream error involving image registration. #ROILS celebrates the significant contributions medical physicists make to #PatientSafety all year long and is grateful for @aapmHQ ’s continued support of the RO-ILS program. Learn more: bit.ly/4AHyb4u #MedicalPhysics #RadiationOncology

Post attachment
Speed of Light - The ASTRO Foundation avatar
⟳ ASTRO retweeted
Speed of Light - The ASTRO Foundation@SpeedofLightFdn·20h

Looking for more information about lung cancer treatment? Watch our patient education video, “Radiation Therapy for Lung Cancer,” on the Speed of Light website to learn more about how radiation therapy works and what patients can expect during treatment. Share this resource with anyone who may benefit from learning more about lung cancer treatment. Learn more: bit.ly/4iJEOf6 @LungAssociation @LUNGevity @GO2forLungCancr @ASTRO_org

Post attachment
ASTRO avatar
ASTRO@ASTRO_org·22h

🚨Deadline Extended: Just 3 DAYS LEFT! Submit your abstract for the 2027 Multidisciplinary Radiopharmaceutical Therapy Symposium by Friday, Nov. 20 Due to popular demand, ASTRO is reopening its call for RPT abstracts! Don't miss this additional opportunity to share your research, discoveries and clinical insights with colleagues. #MRPTS27 Submit your abstract today: bit.ly/4kkkbbZ @ABR_Radiology @SNM_MI @ACRORadOnc @ASCO @SGO_org @RSNA

Post attachment
ASTRO avatar
ASTRO@ASTRO_org·Nov 16

Congratulations to Sibley Memorial Hospital for achieving reaccreditation through ASTRO’s APEx - Accreditation Program for Excellence®. 🎉 ➡️Learn more & join the list of accredited facilities: bit.ly/4haNwDu

Post attachment
ASTRO avatar
ASTRO@ASTRO_org·Nov 16

Help shape the conversation at ASTRO's 69th Annual Meeting: The #ASTRO27 Call for Education Session Proposals is now open! Share your expertise, contribute to the radiation oncology community and bring new perspectives to the educational program. Deadline: Monday, January 11, 2027. Submit now: bit.ly/48EEjOA

Post attachment
ASTRO avatar
ASTRO@ASTRO_org·Nov 16

Join us on Saturday, Dec. 5, from 10:00 a.m. - 5:00 p.m. ET at ASTRO's 2026 Virtual Coding and Coverage Seminar: This one-day virtual seminar will address the many factors that affect this complex and ever-changing aspect of clinical practice, with the goal of making clinical coding easier to understand and apply for your practice. Along with your registration, you will receive an electronic and print version of the 2027 ASTRO Coding Resource. Learn more & register now: bit.ly/4ikuT0q

Post attachment
Fox Chase Cancer Center avatar
⟳ ASTRO retweeted
Fox Chase Cancer Center@FoxChaseCancer·Nov 16

Fox Chase recently welcomed @ASTRO_org CEO Vivek S. Kavadi, MD, for a firsthand look at our adaptive radiation therapy program. Dr. Kavadi met with faculty, observed the technology in practice and discussed advances in radiation oncology. Learn more: bit.ly/4sTyshZ

Post attachment
ASTRO avatar
ASTRO@ASTRO_org·Nov 14

Check out this #RedJournal article from @NRGOnc on the neurocognitive function and quality of life results from a phase II study (NRG/RTOG 0424) of temozolomide-based chemoradiotherapy regimen for high-risk low-grade gliomas. tinyurl.com/rjjswefel

Post attachment
ASTRO avatar
ASTRO@ASTRO_org·Nov 14

New in #RedJournal: Adaptive SBRT boost (30 Gy/5 fx) to residual primary tumor after CRT in unresectable stage III NSCLC without immunotherapy. 2-yr OS 61.5%; BED >94.77 Gy & 3-mo SUVmax ≥4.55 predict locoregional control. tinyurl.com/rjekiraz

Post attachment